SGHT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -6.34%, SMA50 -20.99%, SMA200 4.96%). The stock’s 14-day RSI is 35.22 (weak momentum), while the ATR of 0.34 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.4% below its high and over 162.07% above its low. Average 10-day trading volume of 165.59 thousand shares is below the 3-month average of 186.76 thousand, indicating normal recent market interest.

Sight Sciences, Inc. has 54.41 million shares outstanding. The public float is 35.12 million shares, elevated short interest at 2.10% of float. This equals 829.85 thousand shares. The short ratio is 4.02 days. Institutional investors hold 66.92% of the float. Insiders own 19.98%. Badawi Paul holds 6.12 million shares, D1 Capital Partners L.P. has 3.00 million shares and Badawi David has 1.98 million shares. Over the past six months, insider transactions show net selling. They sold 182.62 thousand shares across 13 transactions.

The stock is currently mid-range between its 52-week high and low $3.11 and $9.24. With a market capitalization of about $286.20 million, Sight Sciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.38). Key stats such as the average daily volume over the past year has been around 186.31 thousand shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, CA, Sight Sciences, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Paul Badawi, the company employs approximately 186 people and listed since July 15, 2021. Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases.

Sight Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.44. This means the shares are trading above this model’s fair value.

Sight Sciences, Inc. generated EPS of -$0.90 over the past year. Five-year average earnings growth is -13.18%. Wall Street analysts project EPS growth of 24.66% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.15. Next year's EPS is expected at $8.20. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 7 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.00. The high target offers 128.14% upside. The low target suggests -23.95% downside. The mean target is $7.58. This offers 44.11% upside. Sight Sciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 26.32%. The prior quarter beat by -46.67%. Over the last six quarters, Apple has recorded several small beats. These include 4.55% in March 05, 2025.

Sight Sciences, Inc. (NASDAQ:SGHT) shares are down -21.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sight Sciences, Inc. trading at a premium to the broader market with a P/E of -7.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.68, suggesting 46.01% upside. Our AI forecast model points to short-term weakness (-5.32% over two weeks), a medium-term rise (49.05% over three months), and a longer-term gain (39.92% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Sight Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.32%, with price expected at $4.98 by August 13, 2026, within a range of $4.81 to $5.18 3-Month Outlook: Projected rise of 49.05%, reaching $7.84 by October 28, 2026, with a range of $7.69 to $7.98. 1-Year Outlook: Projected gain of 39.92%, with price at $7.36 by July 30, 2027, within a range of $0.00 to $10.80.

Sight Sciences, Inc. trades at a P/E ratio of -7.43, slightly below the S&P 500 average, with a price-to-sales ratio of 3.6 and a price-to-book ratio of 5.27 trading at moderately above to book value. The P/FCF stands at -11.28, also below market averages.